Mateon Therapeutics (OTCMKTS:MATN) versus Galera Therapeutics (NASDAQ:GRTX) Critical Contrast

Risk & Volatility

Mateon Therapeutics has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, Galera Therapeutics has a beta of 1.92, meaning that its share price is 92% more volatile than the S&P 500.

Valuation and Earnings

This table compares Mateon Therapeutics and Galera Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mateon Therapeutics	N/A	N/A	-$6.64 million	($0.02)	-3.86
Galera Therapeutics	N/A	N/A	-$59.08 million	($0.10)	-0.21

Mateon Therapeutics is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

0.1% of Mateon Therapeutics shares are owned by institutional investors. Comparatively, 50.8% of Galera Therapeutics shares are owned by institutional investors. 39.2% of Mateon Therapeutics shares are owned by company insiders. Comparatively, 12.9% of Galera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Mateon Therapeutics and Galera Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mateon Therapeutics	N/A	-64.66%	-42.92%
Galera Therapeutics	N/A	N/A	-99.34%

About Mateon Therapeutics

Mateon Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma. The company is headquartered in Agoura Hills, California.

About Galera Therapeutics

Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.